Search Result

Results for "

reduces blood glucose

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (4) SGLT (5) 11β-HSD (1) Adrenergic Receptor (3) Akt (6) Aldose Reductase (1) AMPK (2) Amylases (1) Amyloid-β (2) Apoptosis (7) Autophagy (2) Bacterial (2) Biochemical Assay Reagents (2) c-Myc (2) CDK (2) Claudin (1) Dipeptidyl Peptidase (3) Drug Intermediate (1) Endogenous Metabolite (14) ERK (1) Estrogen Receptor/ERR (1) FABP (1) FBPase (1) GCGR (6) GLP Receptor (3) Glucokinase (1) Glycosidase (9) GPR119 (2) GSK-3 (4) HSP (1) IKK (1) Insulin Receptor (1) Isotope-Labeled Compounds (6) KLF (2) Mitochondrial Metabolism (2) NF-κB (1) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) Phosphatase (3) Phosphorylase (1) PI3K (2) PPAR (8) Reactive Oxygen Species (ROS) (6) Reference Standards (5) Salt-inducible Kinase (SIK) (2) STAT (1) TNF Receptor (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (8) Endocrinology (10) Infection (1) Inflammation/Immunology (12) Metabolic Disease (76) Neurological Disease (9)
Oligonucleotides:	Polymers (1) Antisense Oligonucleotides (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Glucose-6-Phosphate Isomerase (GPI) GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin proline reduces* renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-150012

N-Lactoyl-Phenylalanine 3 Publications Verification Lac-Phe	Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-P5578

A8SGLP-1	GCGR	Metabolic Disease
A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .

HY-P5578A

A8SGLP-1 TFA	GCGR	Metabolic Disease
A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .

HY-14747

Piragliatin RO4389620	Glucokinase	Metabolic Disease
Piragliatin (RO4389620) is an activator for glucokinase, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .

HY-117446

AS-1669058	GPR119	Metabolic Disease
AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .

HY-117446A

AS-1669058 free base	GPR119	Metabolic Disease
AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active *sodium-glucose* cotransporter (SGLT) 2** inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .

HY-118113

BVT-116429	11β-HSD	Others
BVT-116429 is an 11βHSD1 inhibitor with the activity of increasing adiponectin concentration and improving glucose homeostasis in diabetic mice. BVT-116429 can increase plasma adiponectin levels in diabetic KKAy mice, reduce basal insulin levels, and reduce fasting blood glucose levels after 10 days of inhibition, similar to the effect of rosiglitazone.

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin reduces* renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-161281

α-Glucosidase-IN-49	Glycosidase	Metabolic Disease
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC₅₀ of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .

HY-148529

Midaglizole (±)-DG5128 free base; DG5128 free base	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .

HY-159696

ISIS 449884	GCGR	Metabolic Disease
ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-159696A

ISIS 449884 sodium	GCGR	Metabolic Disease
ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-162893

SX29	Glycosidase	Metabolic Disease
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC₅₀ value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .

HY-143226

DK1	Estrogen Receptor/ERR	Metabolic Disease
DK1 is a potent modulator of estrogen related receptor. DK1 has an ability in reducing blood glucose, and impacts the activity of ERRα receptor. DK1 has the potential for the research of diabetes .

HY-144026S

9-PAHSA-d9	Biochemical Assay Reagents	Inflammation/Immunology
9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA, an endogenous fatty acid, reduces blood glucose levels and attenuates inflammation .

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active *sodium glucose* cotransporter (SGLT2)** inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-122120

Rafabegron AJ‐9677	Adrenergic Receptor	Metabolic Disease
Rafabegron (AJ-9677) is a specific beta3-adrenoceptor agonist. Rafabegron can reduce blood glucose, insulin, FFA, and triglyceride levels in diabetic and obese mouse models .

HY-138842

DDN	Insulin Receptor Akt ERK	Metabolic Disease
DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .

HY-174145

GLUT4 activator 3	GLUT	Metabolic Disease
GLUT4 activator 3 (Compound 13a) is an antidiabetic agent targeting GLUT4 translocation in skeletal muscle. GLUT4 activator 3 can promote the translocation of glucose transporter 4 (GLUT4) in skeletal muscle cells. GLUT4 activator 3 reduces blood glucose in STZ-induced diabetic rats .

HY-Y0624

4-Pentenoic acid	Endogenous Metabolite Mitochondrial Metabolism	Metabolic Disease
4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization .

HY-173130

α-Glucosidase-IN-86	Glycosidase	Metabolic Disease Inflammation/Immunology
α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC₅₀ of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .

HY-N11551

Salvifaricin	Others	Others Metabolic Disease
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-W709961

5-OAHSA 1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .

HY-N12353

Stevisalioside A	Phosphatase	Metabolic Disease
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

HY-156277

SP4f	PPAR	Metabolic Disease
SP4f is an activator ofPPAR-γ, with the EC₅₀ of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .

HY-156276

SP4e	PPAR	Metabolic Disease
SP4e is an activator of PPAR-γ, with the EC₅₀ of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .

HY-19904B

(+)-Adomeglivant (+)-LY2409021	Endogenous Metabolite	Metabolic Disease
(+)-Adomeglivant ((+)-LY2409021) is a potent and selective glycogenotropin receptor antagonist with glucose-lowering activity. (+)-Adomeglivant reduces fasting blood glucose levels in both healthy subjects and patients with type 2 diabetes. The use of (+)-Adomeglivant can help investigate the mechanisms of hyperglycemia in type 2 diabetes. The antagonistic effect of (+)-Adomeglivant makes it challenging to assess the metabolic consequences of postprandial hyperglycemia .

HY-148529R

Midaglizole (Standard)	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease
Midaglizole (Standard) is the analytical standard of Midaglizole. This product is intended for research and analytical applications. Midaglizole ((±)-DG5128 free base; DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .

HY-I0144

Thiazolidine	Drug Intermediate	Others
Thiazolidine is a five-membered heterocyclic compound containing sulfur and nitrogen heteroatoms. Thiazolidine is an important intermediate in organic synthesis. Thiazolidine derivatives possess diverse bioactivities, such as anti-tumor, antibacterial and insecticidal activities, and the capacity to reduce blood glucose levels .

HY-161892

FABP4-IN-4	FABP	Metabolic Disease Inflammation/Immunology
FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC₅₀ of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .

HY-170874

PPARγ modulator-2	PPAR	Metabolic Disease
PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for PPARγ that inhibits PPARγ ligand-binding domain (LBD) with an IC₅₀ of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models .

HY-12735

SCH 900822	GCGR	Metabolic Disease Endocrinology
SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes .

HY-117172

CP320626	Phosphorylase	Metabolic Disease
CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC₅₀=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes .

HY-151138

α-Glucosidase-IN-16	Glycosidase	Metabolic Disease
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .

HY-123171

ASP8497	Dipeptidyl Peptidase	Metabolic Disease
ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .

HY-150012R

N-Lactoyl-Phenylalanine (Standard)	Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine (Standard) is the analytical standard of N-Lactoyl-Phenylalanine. This product is intended for research and analytical applications. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-149409

α-Glucosidase-IN-31	Glycosidase	Metabolic Disease
α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC₅₀ value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity .

HY-139792

Besigliptin tosylate SHR117887	Endogenous Metabolite	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-107129

MK-3577	GCGR	Metabolic Disease
MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .

HY-150012S1

N-Lactoyl-Phenylalanine-13C6 Lac-Phe-¹³C₆	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine- ¹³C₆ (Lac-Phe- ¹³C₆) is ¹³C labeled N-Lactoyl-Phenylalanine. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-170572

PB01	Dipeptidyl Peptidase Reactive Oxygen Species (ROS)	Metabolic Disease
PB01 is a DPP-4 inhibitor with an IC₅₀ of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes .

HY-Y0624R

4-Pentenoic acid (Standard)	Reference Standards Endogenous Metabolite Mitochondrial Metabolism	Metabolic Disease
4-Pentenoic acid (Standard) is the analytical standard of 4-Pentenoic acid (HY-Y0624). This product is intended for research and analytical applications. 4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization.

HY-W012241

Dodecanedioic acid	Endogenous Metabolite	Metabolic Disease
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-120974

α-lipoic acid derivative 1	GLUT	Metabolic Disease
α-Lipoic Acid Derivative 1 (Compound AN-7) is an α-lipoic acid derivative that enhances glucose transport in skeletal muscle by releasing active α-lipoic acid (LA), significantly improving glucose metabolism. In L6 skeletal muscle cells, α-Lipoic Acid Derivative 1 significantly increases glucose transport rates, approximately 12 times more potent than the parent compound α-lipoic acid (HY-N0492). In a mild diabetic mouse model, 10 mg/kg of α-Lipoic Acid Derivative 1 administered for two weeks significantly reduced blood glucose levels by 39%. α-Lipoic Acid Derivative 1 shows significant potential in research related to glucose metabolism in diabetes .

HY-163433

α-Glucosidase-IN-57	Glycosidase	Metabolic Disease
α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC₅₀ value of 0.180 μM and a K_i of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research .

HY-163853

Antidiabetic agent 6	GLUT Akt	Metabolic Disease
Antidiabetic agent 6 (Compound 19) is an antidiabetic Agent. Antidiabetic agent 6 stimulates GLUT4 translocation by activation of the PI3K/AKT-dependent signaling pathway. Antidiabetic agent 6 reduces blood glucose levels in Streptozotocin (HY-13753)-induced diabetic rats .

Cat. No.	Product Name	Type

HY-W145521

β-1,3-Glucan

β Glucan

Carbohydrates

β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors .

HY-112624B

Dextran T70 (MW 70,000)

Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)

Drug Delivery Thickeners

Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.

Cat. No.	Product Name	Target	Research Area

HY-P5578

A8SGLP-1	GCGR	Metabolic Disease
A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .

HY-P5578A

A8SGLP-1 TFA	GCGR	Metabolic Disease
A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-150012

N-Lactoyl-Phenylalanine 3 Publications Verification Lac-Phe	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-Y0624

4-Pentenoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Mitochondrial Metabolism
4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization .

HY-W012241

Dodecanedioic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-N2468

Xylobiose 1,4-β-D-Xylobiose; 1,4-D-Xylobiose	Structural Classification Zea mays L. Polysaccharides Classification of Application Fields Gramineae Source classification Other Diseases Plants Disease Research Fields Saccharides	TNF Receptor Claudin HSP
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .

HY-B2163

Astaxanthin Maximum Cited Publications 13 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Whitening Agent Research on Agricultural Breeding Food Research Agricultural Research Microorganisms Sunscreen Terpenoids Pigments Diterpenoids Cosmetic Research Disease Research Fields	PPAR Reactive Oxygen Species (ROS) STAT NF-κB Apoptosis
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .

HY-N11551

Salvifaricin	Artemisia frigida Willd. Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants	Others
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-N12353

Stevisalioside A	Structural Classification Isodon hispidus (Bentham) Murata Polysaccharides Source classification Plants Compositae Saccharides	Phosphatase
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-150012R

N-Lactoyl-Phenylalanine (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
N-Lactoyl-Phenylalanine (Standard) is the analytical standard of N-Lactoyl-Phenylalanine. This product is intended for research and analytical applications. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-Y0624R

4-Pentenoic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Mitochondrial Metabolism
4-Pentenoic acid (Standard) is the analytical standard of 4-Pentenoic acid (HY-Y0624). This product is intended for research and analytical applications. 4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization.

HY-W012241R

Dodecanedioic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Dodecanedioic acid (Standard) is the analytical standard of Dodecanedioic acid (HY-W012241). This product is intended for research and analytical applications. Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-N0330

Momordin Ic 3 Publications Verification	Kochia scoparia L. Schrad. Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Chenopodiaceae Cancer	Apoptosis Autophagy PI3K c-Myc
Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl₄ (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

HY-N0330R

Momordin Ic (Standard)	Kochia scoparia L. Schrad. Triterpenes Structural Classification Terpenoids Source classification Plants Chenopodiaceae	Reference Standards Apoptosis Autophagy PI3K c-Myc
Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

HY-N1570

Pterosin B	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Pteridium aquilinum Inflammation/Immunology Disease Research Fields Pteridiaceae	Salt-inducible Kinase (SIK) KLF Amyloid-β
Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-W014901

Bisphenol F BPF; 4,4'-Dihydroxydiphenylmethane	Classification of Application Fields Orchidaceae Galeola faberi Rolfe Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Reactive Oxygen Species (ROS) Akt GSK-3 Apoptosis
Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .

HY-N1570R

Pterosin B (Standard)	Structural Classification other families Ketones, Aldehydes, Acids Source classification Plants Pteridium aquilinum Pteridiaceae	Reference Standards Salt-inducible Kinase (SIK) KLF Amyloid-β
Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-W014901R

Bisphenol F (Standard) BPF (Standard); 4,4'-Dihydroxydiphenylmethane (Standard)	Orchidaceae Galeola faberi Rolfe Source classification Phenols Polyphenols Plants	Reference Standards Reactive Oxygen Species (ROS) Akt GSK-3 Apoptosis
Bisphenol F (Standard) is the analytical standard of Bisphenol F (HY-W014901). This product is intended for research and analytical applications. Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .

Cat. No.	Product Name	Chemical Structure

HY-150012S1

N-Lactoyl-Phenylalanine-13C6
N-Lactoyl-Phenylalanine- ¹³C₆ (Lac-Phe- ¹³C₆) is ¹³C labeled N-Lactoyl-Phenylalanine. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-W012241S1

Dodecanedioic acid-d4

Dodecanedioic acid-d₄ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W012241S

Dodecanedioic acid-d20

Dodecanedioic acid-d₂₀ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-144026S

9-PAHSA-d9
9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA, an endogenous fatty acid, reduces blood glucose levels and attenuates inflammation .

HY-W777762

Dodecanedioic Acid-13C12

Dodecanedioic Acid- ¹³C₁2 is the ¹³C-labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W014901S1

Bisphenol F-13C12

Bisphenol F- ¹³C₁₂ is the ¹³C labeled Bisphenol F (HY-W014901). Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .

HY-W014901S

Bisphenol F-13C6

Bisphenol F- ¹³C₆ is the ¹³C labeled Bisphenol F (HY-W014901). Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .

Cat. No.	Product Name		Classification